XLO (Xilio Therapeutics, Inc.) Stock Financials & Earnings | Market Cap Arena

XLO (Xilio Therapeutics, Inc.) Stock Financials & Earnings | Market Cap Arena

XLOXilio Therapeutics, Inc.

Mkt Cap$28M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$32M

Net Income (TTM)-$58M

EPS (TTM)-$0.65

Free Cash Flow (TTM)-$18M

Gross Margin50.7%

Op. Margin-137.6%

Net Margin-183.9%

FCF Margin-55.3%

P/S Ratio (TTM)0.9x

P/E Ratio (TTM)—

YoY Rev Growth+588.4%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q4 22	$0	$0	-$23M
Q1 23	$0	$0	-$24M
Q2 23	$0	-$492K	-$20M
Q3 23	$0	$0	-$17M
Q4 23	$0	-$449K	-$18M
Q1 24	$0	$0	-$17M
Q2 24	$2M	$2M	-$15M
Q3 24	$2M	$2M	-$15M
Q4 24	$2M	$2M	-$14M
Q1 25	$3M	$3M	-$14M
Q2 25	$8M	-$7M	-$14M
Q3 25	$19M	$19M	-$2M

Valuation

Quarter	P/S	P/E
Q4 22	—	—
Q1 23	—	—
Q2 23	—	—
Q3 23	—	—
Q4 23	—	—
Q1 24	—	—
Q2 24	12.1x	—
Q3 24	6.2x	—
Q4 24	4.5x	—
Q1 25	3.1x	—
Q2 25	1.9x	—
Q3 25	0.9x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q4 22	-$18M	-$19M
Q1 23	-$25M	-$25M
Q2 23	-$17M	-$17M
Q3 23	-$13M	-$13M
Q4 23	-$13M	-$13M
Q1 24	-$11M	-$11M
Q2 24	$20M	$20M
Q3 24	-$14M	-$14M
Q4 24	-$14M	-$14M
Q1 25	$29M	$29M
Q2 25	-$14M	-$15M
Q3 25	-$17M	-$17M

Capital Expenditures

CapEx

Quarter	CapEx
Q4 22	$509K
Q1 23	$170K
Q2 23	$316K
Q3 23	$0
Q4 23	$0
Q1 24	$0
Q2 24	$21K
Q3 24	$9K
Q4 24	$6K
Q1 25	$22K
Q2 25	$401K
Q3 25	$0

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q4 22	—	+18.5%
Q1 23	—	+10.8%
Q2 23	—	-18.1%
Q3 23	—	-14.1%
Q4 23	—	-21.7%
Q1 24	—	-25.7%
Q2 24	—	-15.2%
Q3 24	—	-1.9%
Q4 24	—	-15.3%
Q1 25	—	-4.0%
Q2 25	+243.0%	+31.6%
Q3 25	+742.5%	+23.3%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q4 22	$2M	—
Q1 23	$2M	—
Q2 23	$2M	—
Q3 23	$2M	—
Q4 23	$0	—
Q1 24	$2M	—
Q2 24	$2M	64.1%
Q3 24	$2M	69.6%
Q4 24	$2M	87.9%
Q1 25	$2M	52.4%
Q2 25	$1M	16.7%
Q3 25	$0	0.0%

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q4 22	$15M	$8M	—
Q1 23	$16M	$7M	—
Q2 23	$13M	—	$6M
Q3 23	$11M	$6M	—
Q4 23	$12M	—	$6M
Q1 24	$10M	$6M	—
Q2 24	$11M	$6M	—
Q3 24	$11M	$6M	—
Q4 24	$9M	$7M	—
Q1 25	$8M	$9M	—
Q2 25	$15M	$7M	—
Q3 25	$14M	—	$6M

War Chest

Quarter	Cash	Short-term Investments	Total
Q4 22	$120M	$0	$120M
Q1 23	$93M	$0	$93M
Q2 23	$75M	$0	$75M
Q3 23	$60M	$0	$60M
Q4 23	$45M	$0	$45M
Q1 24	$34M	$0	$34M
Q2 24	$75M	$0	$75M
Q3 24	$61M	$0	$61M
Q4 24	$55M	$0	$55M
Q1 25	$89M	$0	$89M
Q2 25	$122M	$0	$122M
Q3 25	$104M	$0	$104M

Shares Outstanding

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q4 22	27M	+0.1%
Q1 23	27M	+0.1%
Q2 23	27M	+0.1%
Q3 23	28M	+0.2%
Q4 23	28M	+0.1%
Q1 24	28M	+1.3%
Q2 24	58M	+106.9%
Q3 24	63M	+9.9%
Q4 24	65M	+1.9%
Q1 25	75M	+15.5%
Q2 25	96M	+29.1%
Q3 25	144M	+49.4%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 19	—	—
FY 20	—	—
FY 21	$0	74
FY 22	$0	89
FY 23	$0	73
FY 24	$99K	64